v3.24.3
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses:        
Research and development, net of grants $ 4,203 $ 4,441 $ 11,442 $ 12,260
General and administrative, net of grants 2,106 2,703 6,775 8,488
Total operating expenses 6,309 7,144 18,217 20,748
Loss from operations (6,309) (7,144) (18,217) (20,748)
Other income, net 268 362 781 1,122
Net loss $ (6,041) $ (6,782) $ (17,436) $ (19,626)
Net loss per common share - basic $ (0.11) $ (0.13) $ (0.32) $ (0.39)
Net loss per common share - diluted $ (0.11) $ (0.13) $ (0.32) $ (0.39)
Weighted average common shares outstanding - basic 55,247 50,837 54,161 50,757
Weighted average common shares outstanding - diluted 55,247 50,837 54,161 50,757

Source